You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Popup

Request a contact

Stay informed

Avamys (FF) provides effective relief from the cardinal nasal and ocular symptoms associated with AR* 1

Mean change from baseline in daily individual nasal symptom scores 1

AR in Asthma table

The same results were first published in Vasar M, et al. Allergy Asthma Proc. 2008;29(3):313-321. The figure has been independently created by GSK from the original data.

Most AEs in this study were of mild to moderate intensity and comparable to placebo. The most common AEs reported were: epistaxis, headache, nasopharyngitis, laryngopharyngeal pain. 1

*Global, randomised, double-blind, placebo-controlled, 6-week study evaluating the efficacy and tolerability of intranasal FF in patients ≥12 years of age (n=302) with perennial AR. The primary efficacy measure was mean change from baseline over the 6-week treatment period in daily reflective TNSS.

AR: allergic rhinitis; FF: fluticasone furoate; TNSS: total nasal symptom score.

References:

  1. Vasar M, Houle PA, Douglass JA, et al. Fluticasone furoate nasal spray: Effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. Allergy Asthma Proc. 2008;29(3):313-321.

References

Avamys is a registered trademark of the GlaxoSmithKline group of companies